The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years. “Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.” The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs. It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval. |
Super Bowl to host 22,000 fansChinese President Xi Declares 31st World University Games OpenA glimpse of the Beijing Olympic MuseumPress conference for 2020 Chinese National Athletics Championships held in Shaoxing, ZhejiangSnowfall in Beijing causes flight, train delays and personal injuryXi Leads Way in Combating Beijing, Hebei FloodsXi Orders AllHighlights of opening ceremony for China's 14th National GamesFiji pins growth hopes on Chinese tourists, plans direct flights from HKXi Leads Way in Combating Beijing, Hebei Floods